Abstract
In a randomized double-blinded placebo-controlled study the effects of 100 mg fenofibrate TD were investigated in 22 patients suffering from hyperlipoproteinemia type IIa and IIb with respect to whole-blood viscosity, erythrocyte aggregation, plasma viscosity, fibrinogen, and lipoprotein concentrations. Fenofibrate led to significant decreases of VLDL and LDL lipoprotein concentrations. Fibrinogen and alpha 2 macroglobulin remained constant. Whereas whole-blood and plasma viscosity was reduced significantly, erythrocyte aggregation remained unchanged under fenofibrate. We conclude that the reduction of blood viscosity is due to the change in lipoprotein concentrations, mainly LDL fraction, even if we found no quantitative correlation between the parameters.
Get full access to this article
View all access options for this article.